Patents Assigned to QLT, Inc.
-
Patent number: 9173856Abstract: Disclosed herein are therapeutic regimens for treating or ameliorating a visual disorder associate with an endogenous retinoid deficiency in a subject by administering a therapeutically effective amount of a synthetic retinal derivative or a pharmaceutically acceptable composition comprising a synthetic retinal derivative according to the therapeutic regimen which leads to local recovery of visual functions such as visual fields, visual acuity and retinal sensitivity, among others.Type: GrantFiled: April 19, 2011Date of Patent: November 3, 2015Assignee: QLT INC.Inventors: H. Andrew Strong, Suzanne Cadden
-
Publication number: 20150038582Abstract: Therapeutic regimes for improving visual function in a subject having a deficiency in endogenously produced 11-cis retinal comprising administering the synthetic retinal derivative as a divided dose over 2-7 days then providing a resting period of 7-28 days after which the second dose of the synthetic retinal derivative is administered. Preferred synthetic retinal derivatives are 9- or 11-cis-retinyl esters. Disorders associated with deficiency in endogenously produced 11-cis retinal include retinitis pigmentosa and Leber congenital amaurosis.Type: ApplicationFiled: March 1, 2013Publication date: February 5, 2015Applicant: QLT INC.Inventor: Suzanne Cadden
-
Publication number: 20140094484Abstract: The present invention relates to a rapamycin sustained release delivery system for treatment of diseases responsive to rapamycin. The sustained release delivery system of the invention includes a flowable composition containing rapamycin or a rapamycin derivative, which is capable of providing an implant containing the rapamycin or derivative thereof. The flowable composition may be injected into tissue whereupon it coagulates to become the solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid and rapamycin or a rapamycin derivative.Type: ApplicationFiled: October 2, 2012Publication date: April 3, 2014Applicants: QLT Inc., Tolmar Therapeutics, Inc.Inventors: Philippe Maria Clotaire Margaron, Eric Dadey, Christopher M. Lindemann, Ruihong Li
-
Publication number: 20130101658Abstract: A drug insert is configured for use with an implant. The implant is configured for insertion into a lacrimal canaliculus. The drug insert includes a drug core comprising a therapeutic agent and a polymer; and a sheath body comprising material substantially impermeable to the therapeutic agent, wherein the drug core is positioned within the sheath body. The sheath body is configured to provide an exposed end of the drug core that releases therapeutic agent to an eye when the drug insert is disposed within the implant and the implant is positioned in the lacrimal canaliculus. A distal end of the drug core is sealed with a medical-grade adhesive.Type: ApplicationFiled: October 4, 2012Publication date: April 25, 2013Applicant: QLT INC.Inventor: QLT INC.
-
Publication number: 20120318281Abstract: Lacrimal implants for treating diseases or disorders are disclosed. More particularly, lacrimal implants, methods of making such implants, and methods of treating ocular, respiration, inner ear or other diseases or disorders using such implants are disclosed.Type: ApplicationFiled: August 29, 2012Publication date: December 20, 2012Applicant: QLT INCInventors: Alan R. Rapacki, Valery Rubinchik, John B. Holds, Sylvie Sim, Danny Shen
-
Patent number: 8333726Abstract: Lacrimal implants for treating diseases or disorders are disclosed. More particularly, lacrimal implants, methods of making such implants, and methods of treating ocular, respiration, inner ear or other diseases or disorders using such implants are disclosed.Type: GrantFiled: September 8, 2008Date of Patent: December 18, 2012Assignee: QLT Inc.Inventors: Alan R. Rapacki, Valery Rubinchik, John B. Holds, Sylvie Sim, Danny Shen
-
Publication number: 20120277694Abstract: A punctal plug for insertion through a punctal aperture of an eye. The punctal plug includes a stem configured to be inserted into the punctal aperture and along a canaliculus of the eye, a stopper connected to one end of the stem, the stopper configured to seat against the punctal aperture, and a topical prostaglandin. The stem and the stopper are made from a porous or absorbent material, and wherein the material is saturated with the topical prostaglandin.Type: ApplicationFiled: June 26, 2012Publication date: November 1, 2012Applicant: QLT INC.Inventors: Steven A. Odrich, Liane C. Glazer
-
Publication number: 20120245539Abstract: Lacrimal implants providing secure, wedgable retention within a lacrimal punctum and associated canaliculus of an eye are disclosed. The lacrimal implants can comprise an implant body, including first and second portions, extending from a proximal end of the first portion to a distal end of the second portion. The second portion includes a retention projection. The implant body can also include a cavity longitudinally extending from the proximal end of the first portion toward the second portion, wherein the cavity is shaped and sized to receive an insertable actuator, and wherein the retention projection is configured to bias outward or change orientation when the insertable actuator is seated within the cavity.Type: ApplicationFiled: November 26, 2010Publication date: September 27, 2012Applicant: QLT INC.Inventors: Sascha K. Zarins, David J. Scott, David Tholfsen
-
Publication number: 20120245682Abstract: Surface treated implantable articles and related methods are disclosed. The surface treated implantable articles can be substantially flash-free, include one or more rounded edges, or include an enhanced optical clarity, one or all of which can be produced by polishing. The polishing can include causing the implantable articles to be repeatedly impacted with polishing media when the articles are swelled to an enlarged state. The polishing process can be particularly useful for smoothing lacrimal implants insertable in a lacrimal canaliculus.Type: ApplicationFiled: June 4, 2012Publication date: September 27, 2012Applicant: QLT INC.Inventors: Alan R. Rapacki, Wilhelm Leung
-
Publication number: 20120203162Abstract: The present invention describes an improved photodynamic treatment to treat subfoveal choroidal neovascularization (CNV).Type: ApplicationFiled: April 16, 2012Publication date: August 9, 2012Applicant: QLT Inc.Inventor: Romulus Kimbro BRAZZELL
-
Publication number: 20120187594Abstract: A solid drug core insert can be manufactured by injecting a liquid mixture comprising a therapeutic agent and a matrix precursor into a sheath body. The injection can be conducted at subambient temperatures. The mixture is cured to form a solid drug-matrix core. The therapeutic agent can be a liquid at about room temperature that forms a dispersion of droplets in the matrix material. A surface of the solid drug core is exposed, for example by cutting the tube, and the exposed surface of the solid drug core releases therapeutic quantities of the therapeutic agent when implanted into the patient. In some embodiments, the insert body inhibits release of the therapeutic agent, for example with a material substantially impermeable to the therapeutic agent, such that the therapeutic quantities are released through the exposed surface, thereby avoiding release of the therapeutic agent to non-target tissues.Type: ApplicationFiled: February 7, 2012Publication date: July 26, 2012Applicant: QLT INC.Inventors: Deepank Utkhede, Robert W. Shimizu, Rachna Jain, Stephen Boyd, Hanson S. Gifford, Eugene de Juan, Cary J. Reich
-
Publication number: 20120178806Abstract: Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle are described as retinoid replacement therapies for treating retinal degenerations in humans.Type: ApplicationFiled: September 30, 2009Publication date: July 12, 2012Applicant: QLT INC.Inventor: Ronald Erwin Boch
-
Patent number: 8210902Abstract: Surface treated implantable articles and related methods are disclosed. The surface treated implantable articles can be substantially flash-free, include one or more rounded edges, or include an enhanced optical clarity, one or all of which can be produced by polishing. The polishing can include causing the implantable articles to be repeatedly impacted with polishing media when the articles are swelled to an enlarged state. The polishing process can be particularly useful for smoothing lacrimal implants insertable in a lacrimal canaliculus.Type: GrantFiled: September 5, 2008Date of Patent: July 3, 2012Assignee: QLT Inc.Inventors: Alan R. Rapacki, Wilhelm Leung
-
Patent number: 8158669Abstract: The present invention describes an improved photodynamic treatment to treat subfoveal choroidal neovascularization (CNV).Type: GrantFiled: October 18, 2007Date of Patent: April 17, 2012Assignee: QLT, Inc.Inventor: Romulus K Brazzell
-
Publication number: 20120041356Abstract: The use of a combination of photodynamic therapy and an anti-VEGF agent in the treatment of conditions characterized by unwanted choroidal neovasculature is described. These conditions include wet age-related macular degeneration Preferred anti-VEGF agents are antibodies such as bevacizumab or ranibizumab Photosensitizers may be selected from green porphyrins such as BPD-MA (verteporfin) and the photodynamic activation of the photo sensitizer may be accomplished using a reduced fluence rate. The use may further comprises an anti-inflammatory agent such as dexamethasone.Type: ApplicationFiled: December 16, 2009Publication date: February 16, 2012Applicant: QLT INC.Inventors: H. Andrew Strong, Yong Hao
-
Patent number: 8106038Abstract: This invention relates generally to the field of pharmacotherapeutics and the use of photodynamic therapy (“PDT”). In particular, the invention provides a method for reducing or preventing the effects of inflammation arising from normal dose photodynamic therapy (PDT), which method comprises exposing a target tissue in a subject that has been treated with normal dose PDT treatment to low dose light having a wavelength absorbed by a photosensitizing agent used in said normal dose PDT treatment for a time sufficient to reduce or prevent the effects of inflammation arising from said normal dose PDT treatment. The method is particularly useful in reducing or preventing the effects of inflammation arising from normal dose PDT treatment of ocular tissues.Type: GrantFiled: February 15, 2002Date of Patent: January 31, 2012Assignee: QLT Inc.Inventors: Philippe Maria Clotaire Margaron, Anna M. Richter, Julia G. Levy
-
Publication number: 20110276131Abstract: An implant for insertion through a punctum and into a canalicular lumen of a patient. The implant includes a matrix of material, a therapeutic agent dispersed in the matrix of material, a sheath disposed over a portion of the matrix of material and configured to inhibit the therapeutic agent from being released from the matrix of material into the canalicular lumen and to allow the therapeutic agent to be released from a surface of the matrix of material to a tear film, and a retention structure configured to retain the implant within the canalicular lumen.Type: ApplicationFiled: July 18, 2011Publication date: November 10, 2011Applicant: QLT INC.Inventors: Eugene de Juan, JR., Stephen Boyd, Cary Reich, Alan Rapacki, Hanson S. Gifford, III, Mark Deem
-
Publication number: 20110257266Abstract: Disclosed herein are therapeutic regimens for treating or ameliorating a visual disorder associate with an endogenous retinoid deficiency in a subject by administering a therapeutically effective amount of a synthetic retinal derivative or a pharmaceutically acceptable composition comprising a synthetic retinal derivative according to the therapeutic regimen which leads to local recovery of visual functions such as visual fields, visual acuity and retinal sensitivity, among others.Type: ApplicationFiled: April 19, 2011Publication date: October 20, 2011Applicant: QLT, INC.Inventors: H. Andrew Strong, Suzanne Cadden
-
Patent number: 8034803Abstract: The invention relates to the selection and treatment of subjects afflicted with occult choroidal neovascular lesions, including subjects with age-related macular degeneration, by use of photo dynamic therapy (PDT).Type: GrantFiled: February 6, 2002Date of Patent: October 11, 2011Assignees: QLT Inc., Novartis, A.G.Inventors: H. Andrew Strong, Mohammad Azab, Yong Hao, John Miller Koester, Troy Albert Reaves, Jr.
-
Publication number: 20110202020Abstract: A device for delivering a treatment medium to an eye includes a first body portion configured to be removably inserted and secured in an opening of the eye, and a second body portion supported by the first body portion. At least the second body portion includes a treatment medium, and a coating having an opening through which the treatment medium elutes out of the device.Type: ApplicationFiled: April 7, 2011Publication date: August 18, 2011Applicant: QLT Inc.Inventor: Eliot LAZAR